InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
7
Disclosed sells
0
T+90 hit rate
23%
T+90 mean return
-11.7%
Across 22 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Kelly John Alexander, Chief Financial Officer. Director active across 1 company, notably Precision Biosciences INC. Aggregated, 23 disclosures have been recorded. Split: 7 buys · 0 sell. Total volume traded: €230k. History available since 31 August 2021. The latest transaction was filed on 27 December 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations23 total
3,888 sharesCommon StockSEC:0001628280-26-003147
3,888 sharesCommon StockSEC:0001628280-26-003147:0
1,702 sharesCommon StockSEC:0000950170-25-034006:0
44,368 sharesCommon StockSEC:0000950170-25-008012:0
2,113 shares@ US$4.752.5% of flowCommon StockSEC:0000950170-24-141308:0
Ideal exit: 23 Sept 2025 (T+270)
3,000 shares@ US$6.764.9% of flowCommon StockSEC:0000950170-24-129735:0
Ideal exit: 18 Aug 2025 (T+270)
3,605 sharesCommon StockSEC:0000950170-24-121729:0
454 sharesCommon StockSEC:0000950170-24-072050:0
8,334 shares@ US$12.0023.7% of flowCommon StockSEC:0000950170-24-056140:0
506 shares@ US$18.502.2% of flowCommon StockSEC:0000950170-24-053116:0
116,690 sharesCommon StockSEC:0001209191-24-002121:0
108,188 sharesCommon StockSEC:0001209191-23-054546:0
90,000 shares@ US$0.4810.1% of flowCommon StockSEC:0001209191-23-053784:0
Ideal exit: 14 May 2024 (T+270)
5,951 shares@ US$0.390.5% of flowCommon StockSEC:0001209191-23-048144:0
90,000 shares@ US$0.4810.1% of flowCommon StockSEC:0001209191-23-046874:0
34,091 sharesCommon StockSEC:0001209191-23-035792:0
20,000 shares@ US$0.864.1% of flowCommon StockSEC:0001209191-23-020154:0
Ideal exit: 12 Dec 2023 (T+270)
11,605 shares@ US$0.952.6% of flowCommon StockSEC:0001209191-23-016835:0
37,037 shares@ US$1.3412.8% of flowCommon StockSEC:0001209191-22-051240:0
Ideal exit: 19 Jun 2023 (T+270)
33,784 shares@ US$1.500.048% mcap46.3% of flowCommon StockSEC:0001209191-22-039100:0
Ideal exit: 19 Mar 2023 (T+270)
34,090 sharesCommon StockSEC:0001209191-22-035405:0
16,677 shares@ US$3.080.047% mcap45.0% of flowCommon StockSEC:0001209191-22-020337:0
Ideal exit: 12 Dec 2022 (T+270)
998 shares@ US$10.680.0090% mcap8.7% of flowCommon StockSEC:0001209191-22-016614:0
23 of 23 declarations
About Kelly John Alexander
John Alexander Kelly is the Chief Financial Officer of Precision Biosciences Inc. He oversees the financial management of the company, including budgeting and financial reporting, thereby contributing to the financial health of the company.
